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D936104 Prophylaxis of Atrial Fibrillation FollowingElectrical Cardioversion. A Prospective
Randomized Study Comparing Low-Doee and
Very LOW-DOSSAmlodarone to Propafenone:
Preliminary Remtlte
F.Aequati,F. Forgione, S. Caico, C. Saveri, E. Miglierina, S. Roeei,
S. Repetto, G. Sinaghi. Division of CardiObgM General Hospital of Varese,
Italy
In patients (pts) with chronic atrial fibrillation (AF), restoration of sinus rhythm
(SR) osn be easily achieved by pharmacological or electrical cardioversion
(EC) but reiapse ratea are high, even with the use of antiarrhythmic drugs
(AA). In June 1995 we planned a single-center, prospective, open-label,
randomized study comparing the aafety and effioecy of amiodarone (A) vs
propafenone (P) in maintaining SR in 150 pts with chronic AF successfully
submitted to EC. Pts were randomized to reoeive Iow-doae A (200 mg/day,
group A), very iow-doeeA(100 mglday, group S)or P (675 mgt.i.d., group C).
Ptssesigned to A receiveda Ioadingdose of 1500 mg inthe24hourefollowing
EC. Pts with poet-surgery AF (PSAF) or AF during an acute myocardial
infarction (AMIAF) and ptewith mntraindication to AA [sinus node diefunetion
(SND) and A-V”eonduction defects (AVCD)] were not included in the study.
Ptawith thyroid disease (TO)andshoti-term planned eerdiacsurgery (STCS)
were aieo excluded. Age> 75 yeare, LVEF <407. and left atrial enlargement
were not criteria of exciusion. All pts were then axamined and a 12-lead
ECG obtained at, 1, 3, 6, 12 months of follow-up or when they experienced
symptome suggestive for AF recurrence. From June 1995 to June 1996, 66
pte (54%), out from 159 p~auccessfully submitted to EC, were enrolled.
Reasons for exclusion (73 pts) were: PSAF in 20 (27%), AMIAF in 12 (16%),
TD in 11 (15%), STCS in 9 (12%), SND or AVCD in 12 (16%), refus@
informed consent in 9 pts (12%). Thirty one pte were randomized to group
A, 25 to group B and 30 to group C. Age, sex, underlying heart disease, AF
duration, body weight, left atrial diameter and LVEF were not significantly
different between groups. At a mean follow-up of 7.3 + 3.6 months (range
1-14 months) 25 pte (61%) of group A were still in SR compared to 19 pts
(76%) of group B (p = na) and 17 pts (57%) of group C (p <0.05 vs group
A and p = ns va group S). No serious aide effect was reported, but 2 pte
reduced P for intestinal discomfort and 1 pt died for non-cardiac causes.
Cono/usions: Our preliminary date indicate that Iow-doaeA is a aafe and
effective treatment, superior to P,for maintaining SR after EC for chronic AF.
A similar trend of efficacy can be showed for very low-dose of A.
-1 Pain ThreehO,dfor,nterna, CardiovereionWith
Low or no Sedation
R. Ammer, E. Alt, G. Lehmann, C. Schmitt, J. Pasquantonio, A. Plewan,
K. PMter, A. Sch6mig. L Med. Klinik, Klinikum rechts derlsac Technische
Universit2itMtirrchen, Germany
Seckground: Reoent studies have shown that internal cerdioversion (IC) of
atriai fibriiiatlon (AF) is effective. In this prospective atudy, we have tried to
evaluate the influence of different waveforms on the perception of pain during
IC in patients (pts) with chronic AF.
Methods: IC was performed with low or no sedation in 19 pts. R-wave
triggered, biphasic waveforms of 6 ins/6 ms or 3 ma/3 ms pulse length
(randomly seleoted) and approximately 65% tilt were used starting with a 60
volt (V) test ehcck, then increased in 40 V steps up to a maximum voltage of
520V. Shookewere appiiedvia2 custom-made eleotrode catheters (Eleeath,
Rahway, NJ). In 11 pts (3 female, age 61 * 11 years, LA-diameter 58 + 5
mm, duration of AF 4 + 4 months), &’8 waveforms were used, and in 8 pts
(2 female, age 62 + 5 years, LA-diameter 59 + 5 mm, AF duration 5 +
3 months, none significant), EU3waveforms were used. After cerdiovemion,
each patient was asked to quantify his pain on a scale from 1 to 10 (1 = no
pain, 10= intolerable).
Resu/ts:All ptawere auccesafullycardioverted. Ptsfromthe6/6 waveform
group were convatied to sinus rhythm with lower voltage and lower pain.
Wavsform[ma] 6/6 3/3 p-value
Pain*ore (1-10) 1.3 * 1.1 4.2 & 2.0 p <0.05
Midazolam~mg] 2.3 & 1.8 5.6 & 2.3 p <0.05
CardioveraionEnergy[J] 6.6* 2.8 6.3+ 1.5 n.s,
VoltagepJl 251/114 306/170 p <0.05
Cone/usions:The waveform used in internal derdiovereion seems to have
a major impaot on the patients’ perception of pain. The resulta imply that
energy determines the auooess of a shook, but voltage determine the pain
perceived bythe patient. The uaeof waveforms that deliver greater energy at
iower peak voltages offers the possibility of IC with less sedation and greater
patient tolerance.
EmElImpaired Quality of Life in Patients With AtrielFibrillation ia not Related to AF Frequency or
Duration
M. Paquette, E. Mancuso,”J. Kuruvilla, D. Newman, P. Dorian. The
University of Toronto, Toronto, Canada
The impact of atrial fibrillation (AF) on quality of life (QOL) Is unclear. The
symptom burden and degree of life disruption is highly variable, and may
not be related to objective indices such as frequency or duration of AF
epiecdas. Thirty-five AF patients completed the Medical Outcomes Study
(SF-36), University of Toronto Arrhythmia Sesle (U of T), and the Barsky
Somatization Scale. The frequency, duration, and peroeived aever’ty of AF
episodes were aiso recorded.
Resu/te: 80% of patients were male and median age waa 64 years.
AF was paroxysmal in 45%; 29% and 26% had permanent and persistent
AF, respectively. Median epiaode frequency was 2.5/week with an average
severity rating of 4.9 + 1.3 on a 10 point viaual analog scale.
SF-36 Scele AF CAD Normals
PhysicalFunction 65+ 29* 70& 26 64 k 23
Role-Physical 39• 41*t 51 *40 81 &34
%cial Function 74 + 19*t 85& 21 83& 23
Vitality 47 * 25*t 58& 19 61 &21
General Health 55& 23” 59• 19 72& 20
*p< O.Ot,AFvs. Normals;tp <0.01, AFvs. CAD (r&ent Ml)
Tendeneyto somatize was correlated with lower general health scores on
the SF-36 (by multipie regression, R2= 0.29, p < 0.01). However, frequency
and duration.of episodes were not correlated with any QOL domains (R2 =
0.04-0.10).
Conclusions: QOL is as much or more impaired in patients with AF than
CAD patients; perception of QOL ia unrelated to objective measurea of
disease burden usually empioyed to assess treatment efficacy in AF.
e] ReappraiaalofOptimal lnitialEnergyfor Externel
Cardioversion of Atrial Flutter
S.L. Pinski, E.B. Sgarbosaa, F.J.Jaeger, D. Bash, M. Tobin, R.G. Trohman.
Cleveland Clinic, Cleveland, Ohio, USA
Direct-current cardioversion is oommonly used to restore sinus rhythm in
patients with atrial flutter. Currentiy, initial energies of 25 to 50 J are recom-
mended. However, the optimal energy settings have not been evaluated in
a large aaries of contemporary patients. We compared the effioacy of 50 J
vs. 100J in 296 consecutive patients who underwent their first attempted ex-
ternal esrdioversion for typical atrial flutter. Initial energy wea chosen based
on attending physician preference. One hundred thirty four patients (45%)
received 50 J, and 162 (55%) 100 J. Patients in both groups did not dif-
fer in age, gender, weight, duration of the arrhythmia, postoperative statue,
presence and type of structural heart diseaee, or use of antiarrhythmic druge
(inciuding amiodarone). Patients in the 100 J group had higher incidence
of firet shock oonveraion (83’%vs. 67Yo;p = 0.002), fewer number of total
shocks (1.2 + 0.5 vs. 1.4 + 0.7; p = 0.005), and a trend towards ahorter
procedural room time (39 minutee vs. 54 minutea; p = 0.06). There were no
differences in overall restoration of ainus rhythm (96% vs. 97%), total energy
delivered (152 + 146 J vs. 129* 145 J), or methohexital dose (0.68 + 0.3
vs. 0.69 + 0.3 mg/kg)..No acute complications occurred. Conclusions: an
initial energy of 100 J appeara to be a more efficient choice for restoration of
sinus rhythm in patiente with atrial flutter. It is aesociatad with Iese intensive
reeource consumption without increasea in total energy delivery, anesthetic
requirements or complication.
[-[ Plasma Nitric~xideLeVe,sare Decreaeedin
Patients with Atrial Fibrillation
T. Minamino, M. Kitakaze, H. Sate, H. Asanuma, H. Funaya, K. Node,
Y. Koreteune, M. Hori. The First Dep. of Med., Osaka Univ. School of Med.,
Suita, Japan
Abnormalities of hemostatic condition are found in petienta with atrial fibril-
lation (Af), which may in part account for increased riekof thromboemboiiem.
Since nitric oxide (NO) exerta antithrombctic effeetaand the production of NO
is decreased under ‘WbulenF biood flow condition characteristic of Af, we
hypothesized that NO production ia deoreasad in patients with Af, which may
contribute to the abnormalities of hemostatic cxxsditione.Totest thia hypcthe-
sia,remeasured plaama NOlevels and hemostatic factors irt36pstients with
nonvalvuiar Af (age: 63+2, malalfemaie: 26/10) and 36 age, sex-matched
subjects with sinus rhythm (SR). There were not significant differenoas in the
prevalence of risk factors for stroke, the left atrial aize, and fractional short-
ening of left ventricle between the two groups. Plasma NO (nitrite+ nitrate)
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levels measured using Greiss reagent in patients with Af were decreased
compared with those in aubjeets with SR (mean (interquartile range): 16.5
(6.0-45.6) va. 25.2 (9.2-86.8) mmo!JL,P c 0.05). Plasma levels of Ddimer
(141.4 (34.6-574.1) vs. 65.1 (33.3-217.4) n@mL) and ~-thromboglobulin
(77.4 (31.1-192.7) va. 47.0 (20.4-106.5) n@mL)were increased (P < 0.05)
in patienta with Af Comparedwith those in subjects with SR, suggesting that
fibrin generation and degradation and platelet activation are augmented in
patients with Af. Plaama fibrinogen levels were increaeed in patients with
Af (221.4 (103.6-476.9) vs. 186.5 (76.6-363.4) n@mL, P < 0.05), which is
indicative of increased riak of stroke, and plasma NO and fibrinogen levels
were inversely correlated (n= 72, r =0.37, P < 0.05). These findings suggest
that deereased plasma NO levels may contribute to the cause of abnormal-
ities of hemostatic factors in patients with Af. The decrease of plasma NO
levels may acrxxnt for increased thromboembolic riska in Af.
m936109 EntrainmentofAtriovantricularNodalReantrantTachycardiabyParahisianStimulation:
ElactrophyslologicalEvidenceFora LowerFinal
CommonPathway
F. Anselme, N. Saoudi, H. Poty, B. Letsc. FfouenUrriversityHospita/, France
/rrtroductiorr:The presence ofalowerfinal common pathway (LFCP) between
the AV nodal reentrant tachyqardia (AVNRT)circuit and the His bundle (HB)
remains controversial. Contrary to apiesl ventricular pacing and to pacing
initiated during sinus rhythm, entrainment (E) of AVNRT during parahisian
(PH) stimulation allows accurate measurement of His to atrial (HA) interval
while using the same circuit than that of tachyesrdia. With a LFCP, there is
simultaneous conduction from the low turn around of the circuit to the atrium
(via the fast pathway) and to the HB (antegrade via the LFCP) during AVNRT
whereas the impulse has to retrogradely depolarize sequentially the LFCP
and the fast pathway during PHE. Thus, in presence of a LFCP,HA intewal
duration during AVNRT should be shorter than during PHE.
Methods and Results: PHE was performed in 6 patients (pts, 42 + 21
y) with lypiesl AVNRT. Two decsp@ar Catheterswere, respectively, located
inside the Coronary sinus (CS) and at the HB area. During AVNRT, HA
intervals were measured from the beginning of H to the beginning of A
whereas during PHE from the end of H to the beginning of A. H and A were
reeorckl, respectively, at the distal HB bipole and at the most proximal CS
bipole.
AVNRT Wlieoxonteet PHE
Cvcle Ienoth 313 k 60 293 &57
HA - 59* 12 p <0.05 91 k 16
Resulta are expressed in msec, as mean + etsndard deviation.
Cone/usion:Compared to AVNRT,HA intewal was significantly prolonged
during PHE (+ 32 + 7 msec). In one pt, although PH stimulation was able
to Capture the HB, AVNRT was not affecled. This strongly suggests the
preaence of LFCP during typical AVNRT.
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1937-122] RelationahipoflnducadtOSPOntSnaOUaW:
Implicationsfor ATPTherapy
K.M. Monahan, N. Haliett, T. Hadjis, M.E. Josephson. Beth Lwae/Hospita/,
B@on, MA, USA
In order todefine the relationship betwean VTinducad at pre-dischargestudy
and subsequent spontaneous episodea of VT, we analyzed VT episodes in
patiente with the Medtronic 7218D ICD. Patientswere eligible for incluaion if
they had VT induced at pre-discharge study and experienced a subsequent
epiaode of apontsneoua VT. The study population eonsietedof 19 males (71
& 8 yearn) with previoua Ml (LVEF23%* 18). VT cycle length, response to
ATP, and far-field alsetrogrsm morphology (HVA-HVB) were measured. VT
motpholcgy was judged aa morphologically identical or different based on
analysis by three blinded reviewers.
Resu/fs: The mean time from baaeline study until a spontaneous VT
episode was 162 + 121 daye. The cycle length of induced VT (lVT) was
337 + 53 mace while spontaneous VT (SPVT) was 361 *51 resee: 16/19
(84%) of SPVTdiffered from P/T by <20 msec, and there was no significant
correlation of cycle Iengtha between IVT and SPVT (r = 0.44, p = NS).
Analysis of electrograms revealed SPVT was morphologically distinef from
IVT in 13/19 (66%) of eases. ATP was effective in tarrninating 16/19 (95%) of
IVT and 14/19 (74%) of SPVT. ATP was effeetive in terminating 9/13 (69%)
of morphologically different SPVT and 5/6 (83%) of morphologically identical
SPVT, (p = NS)
Conclusions: Characieristies of VT induced at baseline study mrrelate
poorly with those of subsequent spontaneous episodes. The majority of first
VT.. that occur spontaneously appear to bedifferent tachycardias. Despite
these differences, successful ATP therapy at baeeline is associated with
.qmeessfulATP therapy of spontaneous episodes.
1937-1231 CerebralBloodFlowReepon$$to Ventricular
FibrillationInductionsin ICDImplantation
1.Ostfeld, B. Bruk, A.K. Smolinsky, E. Kaplinsky, M. Eldar, M. Glikson.
Shebs Medical Center and TelAviv University Israel
Trsnacrsnial Doppler ultrssonography (TCD) was used to evaluate the post-
ischemic reaponse of cerebral blood flow to ventricular fibrillation (VF) induc-
tions during ICD implantations. Methods: Cerebral blood flowvelccity(CBFV)
was measured in 38 induced VFS in 8 malea (aged 32-76). At least five min-
utes were allowed between repetitive inductions. Duration and magnitude
of peat-iachemic hyperemic response (PIHR) of CBFV were calculated. Re-
suk Median durations of PIHR in VF episodes of short (3-6 see, n = 4),
intermediate (7–15 see, n = 12), and long (16-35 see, n =22) durations were:
4.5 eec (range 0-13), 50.5 sec (range 6-68), and 81 sec (range 27-102),
respectively. Median magnitude in ahort, intermediate, and long VFS were
4,5% (O-72), 33.5% (10-60), and 58% (20-100), respectively. There was a
correlation between VF duration, PIHR duration, and magnitude (r = 0.82,
r = 0.63), respectively. There was no correlation between PIHR duration or
magnitude and the number of previoua VFSor the time intewal from last VF.
Conclusions: 1) TCD is a uaeful tool for evaluation of cerebral isehemia dur-
ing ICD testing. 2) Very short self-terminating VF episodes result in minimal
ischemic response. 3) Five-minute intewal between inductions is probably
safe, since even with the Iongeat episodes of VF ischemic response Iaats
less than-two minutes. 4) With a five-minute interval between inductions
there is no evidence of cumulative effeet of repeated inductions on cerebral
ischemia.
PI EStimatiOnOfOptimallCDC$p$cit$.cefrOm
HumanStrength-DurationData
C.D. Swerdlow, J.E. Brewer, R.M. Kass, M. Kroll. Cedars-Sinai Medical
Centec Los Angeles, CA, USA
Background: Two theoretical models predict that optimal capacitance (Cm)
for ICD pulses depends both on pathway resistance (R) and the cardiac time
constant of the strength-duration (SD) relation. The Kroll-lmich hyperbolic
(Hyp) model gives the SD curve for average current in terms of the empirieal
time constant, chronsxia (dC).Walcott’sexponential (Exp) model gives the SD
cuwe for leading-edge current in terms of the membrane time constant (z~).
IJsingSc)datsfromanimals, COptis32-56 #F (R= 50 Q). Human SDdatsare
limited. Mat/rods: We studied 12 pta at replacement of epicardial (Epi) ICDS
and 15 pts at implants of active-can pectoral ICDS. Defibrillation threshold
(DFT) was determined for 120 r.tFmonophasic pulses at pulse widths (PW)
of 1.5, 3.0, 7.5, and 15 ms by a delayed 4 step up-down algorfthm with 50
V steps. Hyp and Exp SD cuwes were constructed for each pt. Rasuks:The
table shows DFT in amperes.
Leading-EdgeCurrent DFT Average Current DFT R (Q)
PW 1.5 ms 3 ms 7.5 ms 15 ms 1.5 ms 3 ms 7.5 ms 15 ms
EDI 11.5 S.6 9.0 10.4 9.7 6.2 4.1 2.8 36
ii 13.8 11.2 10,1 10.3 12.2 S.9 5.9 4.0 53
There was a betteFfit’to the Hyp model than the Exp model (r= 0.97 +
0.02-vs. r = 0.64+ 0.12, p < 0.01). For each model, cardiac time conatsnts
were Iesa for TV than Epi (Hyp dc: 3.5 + 0.5 vs. 4.7 + 0.8 ms, p c 0.001;
Exp r~: 6.5 + 2.0 vs. 9.1 + 0.8 ms, p < 0.001), and Cop was less for TV
than Epi (Hyp: 54 +16 vs. 107+ 34 KF, p < 0.001; Exp: 127 +55 vs. 264
+78 YF, p < 0.001). For both TV and Epi, COPI,was less fOrthe HYP model
than the Exp model (p < 0.001). Conclusions: Both models predict that CO@
is greater for humansthan animals and that Cwt is less for TV than Epi.
The average-currentHyp modelpredictaa lowerCwt than the leading-edge
current Exp model.
